Characteristics of patients by type of grafts
. | HLA-identical sibling bone marrow . | . | HLA-identical sibling peripheral blood . | . | Matched unrelated bone marrow . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Variable . | No G-CSF . | G-CSF+ . | No G-CSF . | G-CSF+ . | No G-CSF . | G-CSF+ . | |||
| No. patients | 1153 | 282 | 393 | 216 | 405 | 270 | |||
| Age, y, median (range) | 36 (< 1-69) | 34 (1-60) | 40 (5-66) | 41 (10-65)† | 33 (< 1-59) | 34 (1-62) | |||
| Males, no. (%) | 617 (54) | 156 (55) | 210 (53) | 120 (56) | 244 (60) | 160 (60) | |||
| KPS 80% to 100% at transplantation, no. (%) | 916 (79) | 233 (83) | 277 (70) | 148 (68) | 311 (77) | 229 (85)† | |||
| Disease, no. (%) | |||||||||
| AML | 530 (46) | 160 (57)‡ | 217 (55) | 123 (57) | 139 (34) | 116 (43)† | |||
| CML | 623 (54) | 122 (43) | 176 (45) | 93 (43) | 266 (66) | 154 (57) | |||
| Disease stage,*no. (%) | |||||||||
| Early | 889 (77) | 202 (71) | 256 (65) | 130 (60) | 240 (59) | 145 (53) | |||
| Intermediate | 134 (12) | 39 (14) | 62 (16) | 28 (13) | 93 (23) | 59 (22) | |||
| Advanced | 130 (11) | 41 (15) | 75 (19) | 58 (27) | 72 (18) | 66 (25) | |||
| Donor CMV positive, no. (%) | 323 (28) | 81 (29) | 114 (29) | 70 (32) | 153 (38) | 87 (32) | |||
| Recipient CMV positive, no. (%) | 761 (66) | 178 (63) | 239 (61) | 134 (62) | 198 (49) | 150 (56) | |||
| D/R sex match, no. (%) | |||||||||
| F-M | 257 (22) | 67 (24) | 91 (23) | 58 (27) | 76 (19) | 50 (18) | |||
| Other | 896 (78) | 215 (76) | 302 (77) | 158 (73) | 329 (81) | 220 (82) | |||
| Use of TBI, no. (%) | 271 (23) | 65 (23) | 156 (40) | 75 (35) | 263 (65) | 146 (54)‡ | |||
| Year of transplantation, no. (%) | |||||||||
| 1995-1996 | 556 (48) | 120 (42) | 101 (26) | 58 (27) | 170 (42) | 87 (32)† | |||
| 1997-1998 | 397 (35) | 112 (40) | 159 (40) | 74 (34) | 148 (37) | 110 (41) | |||
| 1999-2000 | 200 (17) | 50 (18) | 133 (34) | 84 (39) | 87 (21) | 73 (27) | |||
| No. centers | 111 | 71 | 69 | 49 | 71 | 46 | |||
| Median follow-up of survivors, mo | 42 (3-87) | 40 (3-77) | 32 (2-77) | 30 (2-81) | 39 (3-82) | 35 (4-81) | |||
. | HLA-identical sibling bone marrow . | . | HLA-identical sibling peripheral blood . | . | Matched unrelated bone marrow . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Variable . | No G-CSF . | G-CSF+ . | No G-CSF . | G-CSF+ . | No G-CSF . | G-CSF+ . | |||
| No. patients | 1153 | 282 | 393 | 216 | 405 | 270 | |||
| Age, y, median (range) | 36 (< 1-69) | 34 (1-60) | 40 (5-66) | 41 (10-65)† | 33 (< 1-59) | 34 (1-62) | |||
| Males, no. (%) | 617 (54) | 156 (55) | 210 (53) | 120 (56) | 244 (60) | 160 (60) | |||
| KPS 80% to 100% at transplantation, no. (%) | 916 (79) | 233 (83) | 277 (70) | 148 (68) | 311 (77) | 229 (85)† | |||
| Disease, no. (%) | |||||||||
| AML | 530 (46) | 160 (57)‡ | 217 (55) | 123 (57) | 139 (34) | 116 (43)† | |||
| CML | 623 (54) | 122 (43) | 176 (45) | 93 (43) | 266 (66) | 154 (57) | |||
| Disease stage,*no. (%) | |||||||||
| Early | 889 (77) | 202 (71) | 256 (65) | 130 (60) | 240 (59) | 145 (53) | |||
| Intermediate | 134 (12) | 39 (14) | 62 (16) | 28 (13) | 93 (23) | 59 (22) | |||
| Advanced | 130 (11) | 41 (15) | 75 (19) | 58 (27) | 72 (18) | 66 (25) | |||
| Donor CMV positive, no. (%) | 323 (28) | 81 (29) | 114 (29) | 70 (32) | 153 (38) | 87 (32) | |||
| Recipient CMV positive, no. (%) | 761 (66) | 178 (63) | 239 (61) | 134 (62) | 198 (49) | 150 (56) | |||
| D/R sex match, no. (%) | |||||||||
| F-M | 257 (22) | 67 (24) | 91 (23) | 58 (27) | 76 (19) | 50 (18) | |||
| Other | 896 (78) | 215 (76) | 302 (77) | 158 (73) | 329 (81) | 220 (82) | |||
| Use of TBI, no. (%) | 271 (23) | 65 (23) | 156 (40) | 75 (35) | 263 (65) | 146 (54)‡ | |||
| Year of transplantation, no. (%) | |||||||||
| 1995-1996 | 556 (48) | 120 (42) | 101 (26) | 58 (27) | 170 (42) | 87 (32)† | |||
| 1997-1998 | 397 (35) | 112 (40) | 159 (40) | 74 (34) | 148 (37) | 110 (41) | |||
| 1999-2000 | 200 (17) | 50 (18) | 133 (34) | 84 (39) | 87 (21) | 73 (27) | |||
| No. centers | 111 | 71 | 69 | 49 | 71 | 46 | |||
| Median follow-up of survivors, mo | 42 (3-87) | 40 (3-77) | 32 (2-77) | 30 (2-81) | 39 (3-82) | 35 (4-81) | |||
G-CSF indicates granulocyte colony stimulating factor; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; CMV, cytomegalovirus; DR, donor-recipient; F, female; M, male; and TBI, total body irradiation.
Disease stage classified as the following: early leukemia indicates first complete remission or first chronic phase; intermediate leukemia, greater than or equal to second complete remission; greater than or equal to second chronic phase or accelerated phase; and advanced leukemia, patients never in remission, in any relapse or blast phase
P < .05
P < .01